Corporate News

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company’s Remuneration Committee it has granted options over an aggregate 5,250,000 shares of £0.00037 each in the capital of the Company to certain Directors and employees of the Company pursuant to the terms of the Company’s Stock Option Plan (the “Share Options”).  In addition, the Company announces that the Chairman and Non-Executive Directors have agreed to reduce their annual cash compensation. 

4,450,000 Share Options have been granted to the ten PDMR’s listed in the table below and 800,000 Share Options have been granted to eight non-PDMR employees. The Share Options will be exercisable at a price of 93p and will vest 25% on 7 July 2022 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2022.

Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information

Dr. Jonthan Allis has agreed to reduce his annual cash compensation from $100,000 to $70,000.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht have agreed reduce their base annual cash compensation from $45,000 to $31,500.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht will continue to receive an additional $5,000 per year for each Board Committee on which they serve.

Following the grant of Share Options referred above, there are 26,438,451 outstanding options and warrants over Polarean’s Ordinary Shares, representing 12.6% of the Company’s total voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation. ¹²⁹Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application (“NDA”) to the FDA for hyperpolarised ¹²⁹Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company’s Remuneration Committee it has granted options over an aggregate 5,250,000 shares of £0.00037 each in the capital of the Company to certain Directors and employees of the Company pursuant to the terms of the Company’s Stock Option Plan (the “Share Options”).  In addition, the Company announces that the Chairman and Non-Executive Directors have agreed to reduce their annual cash compensation. 

4,450,000 Share Options have been granted to the ten PDMR’s listed in the table below and 800,000 Share Options have been granted to eight non-PDMR employees. The Share Options will be exercisable at a price of 93p and will vest 25% on 7 July 2022 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2022.

Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information

Dr. Jonthan Allis has agreed to reduce his annual cash compensation from $100,000 to $70,000.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht have agreed reduce their base annual cash compensation from $45,000 to $31,500.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht will continue to receive an additional $5,000 per year for each Board Committee on which they serve.

Following the grant of Share Options referred above, there are 26,438,451 outstanding options and warrants over Polarean’s Ordinary Shares, representing 12.6% of the Company’s total voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation. ¹²⁹Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application (“NDA”) to the FDA for hyperpolarised ¹²⁹Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company’s Remuneration Committee it has granted options over an aggregate 5,250,000 shares of £0.00037 each in the capital of the Company to certain Directors and employees of the Company pursuant to the terms of the Company’s Stock Option Plan (the “Share Options”).  In addition, the Company announces that the Chairman and Non-Executive Directors have agreed to reduce their annual cash compensation. 

4,450,000 Share Options have been granted to the ten PDMR’s listed in the table below and 800,000 Share Options have been granted to eight non-PDMR employees. The Share Options will be exercisable at a price of 93p and will vest 25% on 7 July 2022 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2022.

Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information

Dr. Jonthan Allis has agreed to reduce his annual cash compensation from $100,000 to $70,000.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht have agreed reduce their base annual cash compensation from $45,000 to $31,500.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht will continue to receive an additional $5,000 per year for each Board Committee on which they serve.

Following the grant of Share Options referred above, there are 26,438,451 outstanding options and warrants over Polarean’s Ordinary Shares, representing 12.6% of the Company’s total voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation. ¹²⁹Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application (“NDA”) to the FDA for hyperpolarised ¹²⁹Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

2020

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company’s Remuneration Committee it has granted options over an aggregate 5,250,000 shares of £0.00037 each in the capital of the Company to certain Directors and employees of the Company pursuant to the terms of the Company’s Stock Option Plan (the “Share Options”).  In addition, the Company announces that the Chairman and Non-Executive Directors have agreed to reduce their annual cash compensation. 

4,450,000 Share Options have been granted to the ten PDMR’s listed in the table below and 800,000 Share Options have been granted to eight non-PDMR employees. The Share Options will be exercisable at a price of 93p and will vest 25% on 7 July 2022 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2022.

Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information

Dr. Jonthan Allis has agreed to reduce his annual cash compensation from $100,000 to $70,000.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht have agreed reduce their base annual cash compensation from $45,000 to $31,500.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht will continue to receive an additional $5,000 per year for each Board Committee on which they serve.

Following the grant of Share Options referred above, there are 26,438,451 outstanding options and warrants over Polarean’s Ordinary Shares, representing 12.6% of the Company’s total voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation. ¹²⁹Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application (“NDA”) to the FDA for hyperpolarised ¹²⁹Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company’s Remuneration Committee it has granted options over an aggregate 5,250,000 shares of £0.00037 each in the capital of the Company to certain Directors and employees of the Company pursuant to the terms of the Company’s Stock Option Plan (the “Share Options”).  In addition, the Company announces that the Chairman and Non-Executive Directors have agreed to reduce their annual cash compensation. 

4,450,000 Share Options have been granted to the ten PDMR’s listed in the table below and 800,000 Share Options have been granted to eight non-PDMR employees. The Share Options will be exercisable at a price of 93p and will vest 25% on 7 July 2022 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2022.

Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information

Dr. Jonthan Allis has agreed to reduce his annual cash compensation from $100,000 to $70,000.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht have agreed reduce their base annual cash compensation from $45,000 to $31,500.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht will continue to receive an additional $5,000 per year for each Board Committee on which they serve.

Following the grant of Share Options referred above, there are 26,438,451 outstanding options and warrants over Polarean’s Ordinary Shares, representing 12.6% of the Company’s total voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation. ¹²⁹Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application (“NDA”) to the FDA for hyperpolarised ¹²⁹Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company’s Remuneration Committee it has granted options over an aggregate 5,250,000 shares of £0.00037 each in the capital of the Company to certain Directors and employees of the Company pursuant to the terms of the Company’s Stock Option Plan (the “Share Options”).  In addition, the Company announces that the Chairman and Non-Executive Directors have agreed to reduce their annual cash compensation. 

4,450,000 Share Options have been granted to the ten PDMR’s listed in the table below and 800,000 Share Options have been granted to eight non-PDMR employees. The Share Options will be exercisable at a price of 93p and will vest 25% on 7 July 2022 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2022.

Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information

Dr. Jonthan Allis has agreed to reduce his annual cash compensation from $100,000 to $70,000.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht have agreed reduce their base annual cash compensation from $45,000 to $31,500.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht will continue to receive an additional $5,000 per year for each Board Committee on which they serve.

Following the grant of Share Options referred above, there are 26,438,451 outstanding options and warrants over Polarean’s Ordinary Shares, representing 12.6% of the Company’s total voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation. ¹²⁹Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application (“NDA”) to the FDA for hyperpolarised ¹²⁹Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.